Stelara 130 mg Konzentrat zur Herstellung einer Infusionslösung שווייץ - גרמנית - Swissmedic (Swiss Agency for Therapeutic Products)

stelara 130 mg konzentrat zur herstellung einer infusionslösung

janssen-cilag ag - ustekinumabum - konzentrat zur herstellung einer infusionslösung - ustekinumabum 130 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, dinatrii edetas, methioninum, aqua ad iniectabile q.s. ad solutionem pro 26 ml, natrium 2.5 µg/ml. - morbus crohn, colitis ulcerosa - biotechnologika

Cosentyx 150 mg Pulver zur Herstellung einer Injektionslösung שווייץ - גרמנית - Swissmedic (Swiss Agency for Therapeutic Products)

cosentyx 150 mg pulver zur herstellung einer injektionslösung

novartis pharma schweiz ag - secukinumabum - pulver zur herstellung einer injektionslösung - vorbereitung cryodesiccata: secukinumabum 150 mg, zucker, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, für glas. - plaque psoriasis bei erwachsenen und kindern ab 6 jahren, ankylosierende spondylitis, psoriatische arthritis, nicht-röntgenologische axiale spondyloarthritis, hidradenitis suppurativa - biotechnologika

Epysqli האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

epysqli

samsung bioepis nl b.v. - eculizumab - hämoglobinurie, paroxysmal - immunsuppressiva - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Ultomiris האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hämoglobinurie, paroxysmal - selektive immunsuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Voydeya 50 mg / 100 mg Filmtabletten שווייץ - גרמנית - Swissmedic (Swiss Agency for Therapeutic Products)

voydeya 50 mg / 100 mg filmtabletten

alexion pharma gmbh - danicopanum - filmtabletten - filmtablette 50 mg: danicopanum 50 mg, hypromellosi acetas succinas, lactosum monohydricum 60.5 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium max. 1.22 mg. filmtablette 100 mg: danicopanum 100 mg, hypromellosi acetas succinas, lactosum monohydricum 121 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium max. 2.44 mg. - als zusatztherapie zu ravulizumab oder eculizumab zur behandlung bei klinisch relevanter extravaskulärer hämolyse nach mindestens 6-monatiger monotherapie mit einem c5-inhibitor bei erwachsenen patienten mit paroxysmaler nächtlicher hämoglobinurie - synthetika

Voydeya 100 mg Filmtabletten שווייץ - גרמנית - Swissmedic (Swiss Agency for Therapeutic Products)

voydeya 100 mg filmtabletten

alexion pharma gmbh - danicopanum - filmtabletten - danicopanum 100 mg, hypromellosi acetas succinas, lactosum monohydricum 121 mg, cellulosum microcristallinum, carmellosum natricum conexum, natrii laurilsulfas, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, pro compresso obducto corresp. natrium max. 2.44 mg. - als zusatztherapie zu ravulizumab oder eculizumab zur behandlung bei klinisch relevanter extravaskulärer hämolyse nach mindestens 6-monatiger monotherapie mit einem c5-inhibitor bei erwachsenen patienten mit paroxysmaler nächtlicher hämoglobinurie - synthetika

Aspaveli האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

aspaveli

swedish orphan biovitrum ab (publ) - pegcetacoplan - hämoglobinurie, paroxysmal - immunsuppressiva - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Kyntheum האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

kyntheum

leo pharma a/s - brodalumab - psoriasis - immunsuppressiva - kyntheum ist indiziert zur behandlung von mittelschwerer bis schwerer plaque-psoriasis bei erwachsenen patienten, die kandidaten für eine systemische therapie sind.

Skyrizi האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunsuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Bimzelx האיחוד האירופי - גרמנית - EMA (European Medicines Agency)

bimzelx

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressiva - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.